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Abstract: Trazodone is approved by the Food and Drug Administration 
(FDA) for the treatment of depression and anxiety in humans, it can 
perform these functions due to its selective serotonin receptor antagonism 
and reuptake inhibition properties. Trazodone has not been approved for 
animals by the FDA but it is legally prescribed by veterinarians as an off-
label drug for dogs and cats. This review describes trazodone’s 
mechanism of action, pharmacokinetic properties and adverse effects and 
summarizes the benefits of trazodone for non-approved FDA indications 
to reduce anxiety, behavioral stress, sedation, pre-and post-operation 
stress. It also discusses its cardiac safety profile for dogs and cats. As few 
clinical trials have been conducted to evaluate trazodone’s efficacy for 
treatment of the many behavioral and medical conditions in animals, large 
and randomized controlled clinical trials are still needed to confirm its 
efficacy in clinical practice. 
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Introduction 
Trazodone, a second-generation triazolopyridine 
derivative (Fig. 1), was approved in the ‘70s for the 
treatment of depression and still represents an effective 
therapeutic option for depressive disorders with or 
without an anxiety component. Beyond its antidepressant 
activity, trazodone was also found to be beneficial in the 
off-label treatment of medical and psychiatric conditions 
such as insomnia, anxiety, post-traumatic stress, 
obsessive compulsive and feeding and eating disorders, 
behavioral disturbances associated with cognitive 
dysfunction, sexual dysfunction, certain pain conditions and 
rehabilitation after acute ischemic stroke (Bossini et al., 
2012; Khouzam, 2017; Stahl, 2008). Trazodone 
selectively antagonizes serotoninergic (5-HT2A and 5-
HT2C) receptors and serotonin reuptake inhibition 
(Saletu-Zyhlarz et al., 2003; Stahl, 2009). Trazodone is a 
moderately potent α-adrenoceptor and histaminergic (H1) 
antagonist and possesses anxiolytic and hypnotic properties 
(Stahl, 2009). Despite the existence of this compound for 
nearly 40 years, its mechanism of action has not been fully 
clarified and continues to be the subject of research. 
Mechanism of Action 
The main pharmacological property of trazodone is 
its potent competitive binding to 5-HT2A receptor 
antagonists. At a very low dose (1 mg) trazodone 
occupies about half of the 5-HT2A receptors (Stahl, 
2009). At low to moderate doses (25-150 mg), trazodone 
mainly acts to antagonize postsynaptic 5-HT2A 
receptors as well as histaminic (H1) and adrenergic (α-1) 
receptors, which may account for some of its hypnotic 
effects. At higher doses (150-600 mg), trazodone also 
acts as an antagonist at postsynaptic 5-HT2A/2C receptors 
as well as blocking the Serotonin Transporter (SERT) on 
the presynaptic neuron (Stahl, 2009). The latter dose range 
has been used to produce an antidepressant effect (Stahl, 
2009). Trazodone’s ability to block SERT is at least 100 
times less potent than its ability to block the 5-HT2A 
receptors (Stahl, 2009). The dual action of 5-HT2A 
antagonism and SERT inhibition leads to positive clinical 
pharmacological results (Stahl, 2009).  
In humans, trazodone is converted by Cytochrome 
(CYP) 3A4 into an active metabolite known as meta-
chloro-phenyl piperazine (mCPP) (Fig. 1). This 
metabolite has high affinity for a number of serotonin 
receptors as 5-HT2C>5-HT2A. It acts as an agonist, 
whereas trazodone acts as an antagonist at 5-HT2A and 
5-HT2C receptors. These pharmacologic actions of 
mCPP may contribute to the net effects of trazodone and 
could probably mitigate trazodone’s antagonism on 5-
HT2A and 5-HT2C receptors. Because plasma and brain 
levels of mCPP appear to be less than 10% of those of 
trazodone, as a result, the antagonist action of trazodone 
appears to overwhelm any effects of mCPP. In short, any 
antagonism that mCPP might have on 5-HT2A and 5-
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HT2C receptors seems to be negligible. However, 
possible interactions between mCPP and other drugs 
metabolized by CYP3A4 may modify trazodone’s 
pharmacologic effects (Stahl, 2009). 
Pharmacokinetic Studies 
As trazodone is used for treating depression and 
anxiety disorders in humans, there are reports on the 
pharmacokinetics of trazodone in humans (Bayer et al., 
1983; Catanese and Lisciani, 1970; Greenblatt et al., 
1987; Jackson et al., 1982; Mercolini et al., 2008; Nilsen 
and Dale, 1992; Si et al., 1991; Vatassery et al., 1997). 
However, the pharmacokinetics of this drug has been 
sparsely documented in dogs (Catanese and Lisciani, 1970; 
Jay et al., 2013), in rats (Catanese and Lisciani, 1970; 
DeVane et al., 1999) and no reports are presented in other 
species, particularly in cats. 
Two pharmacokinetics studies have been performed 
in dogs. The first kinetics study was performed in the 
‘70s. This investigated the absorption and distribution of 
trazodone in a rat, dog and human models. It showed that 
trazodone was absorbed less in dogs compared to 
humans but more than in rats (Catanese and Lisciani, 
1970). In that study, it was reported that Cmax was 2.5 µg 
mL
−1
 and 4.8 µg mL
−1
 for dogs that received trazodone 
orally at a dose of 20 mg kg
−1
 and 50 mg kg
−1
, 
respectively (Catanese and Lisciani, 1970).  
Over 40 year later, another pharmacokinetic study 
was conducted in adult male dogs to observe the effects 
of trazodone administered at 8 mg kg
−1
 as a single dose 
both in intravenous (IV) and oral (PO) administrations. 
Results indicated that the PO administration was better 
tolerated in all dogs compared to the IV administration. 
Substantial adverse effects, tachycardia and behavior 
disinhibition, were noted with IV administration. The PO 
route resulted in acceptable absolute bioavailability 
(84.6%), although considerable variability in Tmax was 
found (Jay et al., 2013). Since adverse effects occurred 
after IV administration, a substantial reduction of the dose 
is recommended when the drug is used via parenteral 
routes (Jay et al., 2013). Notably, the injectable solution of 
trazodone is not yet available for clinical practice. 
A search for information on the pharmacokinetics of 
trazodone in cats was also attempted from different 
scientific data bases; however, no reports were found for 
this species. In contrast, two clinical studies of trazodone 
that reported sedative and anxiolytic properties in cats 
were found (Orlando et al., 2016; Stevens et al., 2016). 
Although there is a lack of trazodone studies in cats, 
trazodone has been documented to be administered at 
1-2 mg kg
−1
 in this animal species (Perrin et al., 2014).  
The active metabolite (mCPP) of trazodone has been 
studied in humans (Rotzinger et al., 1998) and in rats 
(DeVane et al., 1999). However, no data has been 
reported regarding this metabolite in dogs and cats yet. 
Further studies are needed to detail the pharmacokinetic 
pattern for this metabolite in these two animal species. 
Fasting status has been reported to affect the PK of 
oral trazodone. Jay et al. (2013) reported that presence of 
food in the upper gastrointestinal tract may delay 
absorption of trazodone in dogs. Trazodone’s Cmax and 
Tmax may be improved with fasting. Indeed, the Cmax 
peak was within the range 2.5-7.5 h in fasting dogs 
(Catanese and Lisciani, 1970; Jay et al., 2013). The Tmax 
was shortened to 0.5 h when animals were fed 1 h prior 
to drug administration (Jay et al., 2013). Tmax was 
variable in individual animals as shown by Jay et al. 
(2013); 5 of 6 dogs had a Tmax value between 8-10 h 
while 1 dog had a value of 0.5 h.  
Pharmacokinetic parameters of trazodone have 
also been shown to vary with age and sex in humans 
(Bayer et al., 1983; Greenblatt et al., 1987). It has been 
reported that Cmax and Tmax were comparable in both young 
and elderly, but the area under the plasma concentration-
time curve of the drug was significantly greater in the latter 
after a single oral dose of 100 mg trazodone (Bayer et al., 
1983). Other studies indicated that Tmax and T½ were greater 
in the elderly than in the young, as well as in women than 
men after 50 mg oral dose of trazodone in 43 healthy 
subjects (Greenblatt et al., 1987). As few pharmacokinetic 
studies are reported in dogs, the pharmacokinetics of 
trazodone in these animals should be further investigated on 
the base of animal age, sex and breed. 
Side Effects of Trazodone  
The known adverse effects associated with oral 
administration of trazodone in dogs and cats are 
basically mild and well-tolerated. The most common 
adverse effects of oral trazodone include gagging, 
vomiting, colitis, sedation, increased appetite, 
paradoxical excitement and panting, hyper salivation and 
behavior disinhibition in dogs (Gilbert-Gregory et al., 
2016; Gruen and Sherman, 2008; Jay et al., 2013) and 
sedation and behavior disinhibition (struggling, 
aggression and vocalization) in cats (Orlando et al., 
2016; Stevens et al., 2016). Trazodone may not cause 
cardiovascular depression in dogs and cats after oral 
administration (Jay et al., 2013; Orlando et al., 2016) 
although some studies reported this adverse event in 
humans (Rausch et al., 1984; Reeves and Bullen, 1995; 
Service and Waring, 2008). However, tachycardia was 
reported in experimental dogs immediately after IV 
administration at high trazodone blood concentrations 
(Jay et al., 2013) and in anesthetized dogs when 
compared with imipramine at the same dose after IV 
administration (Gomoll et al., 1979; Gomoll and Byrne, 
1979; Je and Aw, 1982). Intraoperative hypertension and 
bradycardia developed in healthy dogs undergoing 
anesthesia for orthopedic surgery when compared with 
acepromazine (Murphy et al., 2017). Other adverse 
events such as priapism (seldom reported in humans) 
was found in 1 out of 15 dogs that received trazodone 24 
h after undergoing anesthesia for orthopedic surgery 
(Murphy et al., 2017). 
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Fig. 1. Chemical structure of trazodone and mCPP 
 
Trazodone is reported to have potential risk for the 
serotonin syndrome when used with other Selective 
Serotonin Reuptake Inhibitor (SSRI) and/or Tricyclic 
Antidepressant (TCA) agents. Although serotonin 
syndrome has not been described in animals after 
trazodone administration, it is likely that trazodone can 
be used as an adjunctive agent in combination with other 
behavioral drugs, TCA or SSRI, opioid drugs, and 
antimicrobials. Former studies reported that it was well 
tolerated over a wide dose range in dogs (Gilbert-
Gregory et al., 2016; Gruen et al., 2014; Gruen and 
Sherman, 2008) and probably in cats as well. However, 
clinicians that are unfamiliar with combined use of 
serotonin enhancing medications are strongly 
recommended to ensure safety and efficacy of trazodone 
(Gilbert-Gregory et al., 2016). 
The safety profile of trazodone has been speculated 
to not be affected by breed, age, or dose in dogs (Gilbert-
Gregory et al., 2016; Gruen et al., 2014; Gruen and 
Sherman, 2008) and cats (Orlando et al., 2016; Stevens et 
al., 2016). However there is no specific report to confirm 
and this issue should be further investigated. Most side 
effects resolve with time and monitoring is the best 
response to the appearance of mild to moderate side 
effects. For the dose regimen it is best to begin at the 
lower end of the dosage range to limit side effects. 
Indeed, administering a half dose for three days and 
then gradually tapering up as needed resulted in less 
side effects in dogs (Gruen and Sherman, 2008). 
Trazodone Use for Anxiety  
Due to extensive use of trazodone for treating 
depressive and anxiety disorders as well as medical and 
psychiatric conditions in humans, its off label use for the 
treatment of signs of anxiety in dogs and cats has 
recently gained popularity. 
Canine and feline anxiety disorders such as travel, 
separation, noise phobia, veterinary visits and 
hospitalization are common but probably under-estimated. 
The first report on the use of trazodone for treating anxiety 
disorders including separation, storm, noise, inoculation and 
travel phobia, generalized anxiety and canine compulsive 
disorder in dogs showed that trazodone alone or in 
combination with other medications including tramadol, 
NSAIDs, antimicrobials and various behavior-modifying 
drugs induced a few adverse effects (gastrointestinal 
distress, behavioral changes, or sedation). It was tolerated 
over a wide dose range and calmed behavior in various 
breeds, sexes and ages of dogs (Gruen and Sherman, 2008). 
The daily medication ranged from 1.9-16.2 mg kg
−1
 but 
should not exceed 300 to 600 mg/24 h. During a particular 
event (e.g. storm phobia) however, the daily dose can be 
cumulated as needed to a dose in the range 2.2 to 14.0 mg 
kg
−1
 (Gruen and Sherman, 2008) (Table 1). Because this 
finding is extrapolated from a retrospective case series, 
further controlled studies of dose range, efficacy and safety 
are required to provide an additional therapeutic option for 
using trazodone in dogs that are unresponsive to 
conventional treatments (Gruen and Sherman, 2008). 
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Table 1. The doses of trazodone for various behavioral and medical conditions 
Conditions Dogs Cats References 
Anxiety - 1.9-16.5 mg kg−1 q 24 h (for daily - 7.7-15.2 mg kg−1 q 24 h for  Gruen and Sherman (2008) 
 medication) or 1.7-19.5 mg kg−1 q 24 h 1-1.5 h prior to a veterinary Stevens et al. (2016) 
 (combined daily [q 8-24 h] and as-needed  visit Herron and Shreyer (2014) 
 administration) or 2.2-14 mg kg−1 q 24 h  
 (as-needed administration) for general anxiety  
 - 4-12 mg kg−1 q 24 h for 1.5 h prior to a  
 veterinary visit 
Behavioral - 3-7 mg kg−1 alone or combine with NSAIDs, - No published dose  Gilbert-Gregory et al. (2016) 
stress tramadol and other medications 
Sedation - 3-5 mg kg−1 q 12-24 h - 10.6-16.7 mg kg−1 q 24 h Orlando et al. (2016) 
   for 50 mg tablet 
  - 21.3-33.3 mg kg−1 q 24 h for Gruen and Sherman (2008)  
  100 mg tablet 
Pre-operation - 5-7 mg kg−1 given prior 2 h combines with - No published dose Murphy et al. (2017) 
 opioid as premedication for anesthesia  
 and orthopedic surgery 
Post-operation - 3.5 mg kg−1 combine with tramadol for 3 days - No published dose Gruen et al. (2014) 
 and then 7 mg kg−1 q 12 h or7-10 mg kg−1 q 8  
 h as-needed for 4-12 weeks for orthopedic surgery 
 
The second study reported that trazodone has been 
recommended to promote low-stress veterinary visits for 
dogs (Herron and Shreyer, 2014) and cats (Stevens et al., 
2016) that have signs of anxiety. In dogs, trazodone 
(dose 4 to 12 mg kg
−1
, not exceeding 300 mg per animal) 
administered by the owner 1.5 h prior to a veterinary 
visit significantly reduced stress associated with 
handling and examination (Herron and Shreyer, 2014). 
In cats, a dose between 7.7 and 15.2 mg kg
−1
 of 
trazodone administered by the owner 1-1.5 h prior to a 
veterinary visit resulted in significantly fewer signs of 
transport- and examination-related anxiety compared to 
placebo as control. Trazodone was well tolerated by 
most cats in the double-blind randomized crossover 
study (Stevens et al., 2016). Because of the low numbers 
of cats of various ages, few cats had one or more of the 
evaluated signs of anxiety or presence of adverse events 
(vocalization and agitation). Pharmacodynamic and 
pharmacokinetic studies should be performed to ensure 
the safety and efficacy of this drug for treatment of 
anxiety in cats (Stevens et al., 2016). 
Trazodone Use for Behavioral Signs of Stress  
Hospitalized animals such as dogs specifically have 
signs of acute and chronic psychogenic stress resulting 
from invasive procedures, novel environments, 
confinement and separation from familiar individuals 
(Gilbert-Gregory et al., 2016). Trazodone has been 
applied to treat behavioral signs of stress in dogs 
during hospitalization but no report has been 
investigated in cats. According to a recent study, 
trazodone in a dose range from 2.83 to 6.75 mg kg
−1
 
reduced stress-related signs and behaviors of 
hospitalized dogs when used alone or in combination 
with NSAIDs, tramadol and other medications without 
any adverse events (Gilbert-Gregory et al., 2016). 
Furthermore, trazodone reduced hospitalization time in 
dogs. Gilbert-Gregory et al. (2016) showed that dogs with 
signs of behavioral stress treated with trazodone were 
hospitalized for 1-4 days (mean 1.5±0.8 days) compared 
to the environmentally matched dogs that were 
hospitalized for 1-11 days (mean 2.0±2.0 days) (P = 0.01). 
Trazodone Use for Sedation  
Treating the pain and anxiety of pet animals is critical 
to patient satisfaction and quality of care. However, 
sedation is also necessary to facilitate handling and to allow 
clinical procedures to be performed correctly and safely 
(Clements, 2006) during veterinary visits (Gruen and 
Sherman, 2008; Orlando et al., 2016). For hospitalized 
patients, trazodone is used commonly to eliminate the 
need for IV administration of sedatives, such as 
acepromazine and dexmedetomidine (Jay et al., 2013). 
There is recently published data on use of trazodone 
for sedation in cats but no data available for dogs. A 
pilot study on laboratory cats receiving trazodone at 50, 
75 and 100 mg PO (10.6-16.7, 16.0-25 and 21.3-33.3 mg 
kg
−1
, respectively) and one placebo control indicated that 
trazodone was likely well tolerated in cats and caused 
appreciable sedation at all doses. Sedation as measured 
by activity reduction was 83%, 46% and 66% at the 
doses of 50, 75 and 100 mg, respectively. Mean peak 
sedation ranged from 1-3 h after dosing and no severe or 
mild adverse responses were found. Only struggling, 
aggression and vocalization were noted (Orlando et al., 
2016). However, because the examinations were 
performed before the time of the pharmacodynamics 
peak, the sedation effect could be larger if the 
assessment was performed later. Some limitations were 
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observed in this study; not all doses of trazodone were 
randomized, subjects were limited to neutered male cats, 
cats were housed in a single room with visual access 
to the other cats and one cat did not receive a full dose 
on one treatment day (100 mg). In addition, the 
treatment was voluntarily ingested rather than being 
administered and not all cats received the medication 
in similar types or amounts of food. These limitations 
may have slightly altered absorption rates of 
trazodone, observations on animal behavior and 
measurements recorded (Orlando et al., 2016). 
Although it has not been studied in dogs, it is 
reported that trazodone at the initial target dose 
administration can cause sedation in some dogs if 
administered at more than a half of the initial target dose 
based on animal weight (Gruen and Sherman, 2008).  
Trazodone Pre-Operative Use  
The pre-operative use of trazodone has been less well 
documented in literature, however it is commonly used, 
off-label, for this practice (Gilbert-Gregory et al., 2016; 
Murphy et al., 2017). Veterinary hospitals are using 
trazodone to pre-medicate dogs in combination with 
opioid agents (Murphy et al., 2017) but no information is 
reported in cats yet. In a prospective study in 
hospitalized dogs undergoing general anesthesia for 
orthopedic surgery, trazodone (5-7 mg kg
−1
 dose), when 
used in combination with upload drugs, showed similar 
cardiovascular effects compared to acepromazine 
(Murphy et al., 2017). 
Trazodone Use for Post-Operative Confinement  
Stress caused by a visit to the veterinary clinic has 
been highlighted to have negative impacts on animals, 
owners and veterinarians. Furthermore, the additional 
stress of surgery and the possibility of an extended stay 
in the veterinary hospital wards can increase the 
recovery period and can be of concern for the pet 
animals’ welfare (Gruen et al., 2014). In dogs especially 
if young, active, healthy and unaccustomed to 
confinement, the implementation of postsurgical 
instructions are often challenging to owners and 
sometimes for veterinarians as well (Gruen et al., 2014; 
Guthrie et al., 2012). This likely applies to cats as well. 
Consequently, failure to comply with activity restriction 
may lead to protracted recovery or even surgical 
treatment failure possibly requiring a second surgical 
procedure (Knudsen et al., 2012). Trazodone is 
administered orally for acute and chronic anxiolysis to 
facilitate cage rest and activity restriction in dogs after 
orthopedic surgery (Jay et al., 2013) and as well as for pre-
or post-surgery of stress or anxious dogs during subsequent 
hospitalization (Gilbert-Gregory et al., 2016).  
A recent study on 36 client-owned dogs (19 females 
and 17 males; 3.0±2.46 year-old and 32.0±10.6 kg body 
weight) that underwent orthopedic surgery and were 
treated with trazodone for 4 weeks combined with a 
short tramadol treatment (discontinued after 3 days), 
antimicrobials and other medications showed that 
trazodone moderately to markedly improved 
confinement tolerance and calmness. Median onset of 
action of trazodone was 31-45 min and median duration 
of action was ≥ 4 has reported by owners. Trazodone 
was administered at a dose of 3.5 mg kg
−1
, PO, q 12 h 
combined with tramadol for three days. After three days, 
the trazodone dose was increased to approximately 7 mg 
kg
−1
, PO, q 12 h. If needed, trazodone dose was 
increased from 7 to 10 mg kg
−1
, PO, q 8 h. Furthermore, 
the increased trazodone dose (n = 25) dogs did not differ 
in age and weight compared to the standard treatment 
dogs (n = 11) (Gruen et al., 2014). Although trazodone 
improved tolerance and calmness after surgeries, adverse 
events were observed in 55.5% of patients and included 
soft stool, constipation, thirst, restlessness/agitation, 
aggression, moaning, drowsiness, somnolence, panting, 
teeth chattering, drooling, paranoia and incontinence 
(Gruen et al., 2014).  
To date, no reports have been published for the use of 
trazodone for post-operative confinement in cats. 
However, it could be suggested for cats as trazodone is 
used effectively in dogs for post-operative confinement. 
Trazodone Safety on the Cardiac System 
Trazodone is as antidepressant and anxioytic drug 
that at clinical doses produces very few cardiovascular 
side effects in humans (Munday et al., 1975). A study 
reported that 0.3, 3 and 3 to 10 mg kg
−1
 of trazodone 
lowered arterial blood pressure, slowed heart rate and 
reduced myocardial contractile force respectively, unlike 
imipramine (a TCA drug) (Gomoll et al., 1979). Another 
report examined the effects of trazodone on several 
aspects of cardiac conduction compared to imipramine 
over a dose range 1-30 mg kg
−1
, IV. This study revealed 
that trazodone promoted no evidence of heart block or 
sign of rhythm disturbances other than slowing in normal 
sinus rhythm when compared with imipramine in 
closed-chest pentobarbital-anesthetized adult dogs 
(Gomoll and Byrne, 1979). The last report aimed to 
evaluate the effects of trazodone on intracardiac 
condition in the anesthetized dog compared to 
imipramine, this indicated that trazodone lowered 
heart rate and prolonged the Q-Tc interval potentially 
suggesting greater safety of trazodone as a new and 
distinct antidepressant drug (Je and Aw, 1982). 
Conclusion 
Trazodone is approved by the FDA for the treatment 
of depressant and anxiolytic disorders in humans. 
However, trazodone has been legally prescribed by 
veterinarians as an off-label drug in dogs and cats. Its 
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pharmacological effects have been reported to reduce 
anxiety, behavioral stress, sedation, pre-and post-
operation stress and do not affect cardiac conditions in 
dogs and cats in context of promoting animal welfare.  
Trazodone’s beneficial effects and common use have 
been reported on small sample sizes in relatively few 
clinical trials. Larger and randomized controlled clinical 
trials are necessary to soundly illustrate its efficacy in 
treating the diverse conditions for which it is used in 
clinical practice. Other studies would also need to 
demonstrate the risk and benefit ratio in different 
conditions for which trazodone has been prescribed. It is 
anticipated that this review will provide veterinarians 
with the information that they need to feel comfortable in 
prescribing trazodone for various’ off-label behavioral 
and medical conditions in dogs and cats.  
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